Overall, our study benefits from multiomics data and provides new insights into the clinical, genomic, epigenetic and biological conditions of IDH-mt astrocytoma and grade 2 oligodendroglioma. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).